公开(公告)号：WO2008052043A2

公开(公告)日：2008-05-02

申请号：PCT/US2007/082363

申请日：2007-10-24

Applicant: COGENESYS, INC. ,  ROSEN, Craig, A. ,  BELL, Adam, C. ,  SANYAL, Indrajit ,  LAFLEUR, David

Inventor： ROSEN, Craig, A. ,  BELL, Adam, C. ,  SANYAL, Indrajit ,  LAFLEUR, David

IPC: C07K14/435

CPC classification number: C07K14/665 ,  C07K14/4715 ,  C07K2319/00

Abstract: Disclosed are fusion proteins that include an opioid receptor agonist protein, or a fragment, variant, or an analog thereof fused to a serum protein. Suitable serum proteins for the fusion proteins in albumin, alpha- fetoprotein (AFP) and albumin- AFP hybrid proteins. The fusion proteins have opioid receptor agonist activity. Typically, the fusion proteins may exhibit extended or stabilized opioid receptor agonist activity in vivo or in vitro relative to an opioid receptor agonist that is not fused to the serum protein.

Abstract translation: 公开了融合蛋白，其包含与血清蛋白融合的阿片受体激动剂蛋白或其片段，变体或类似物。 用于白蛋白，甲胎蛋白（AFP）和白蛋白AFP杂交蛋白中的融合蛋白的合适的血清蛋白。 融合蛋白具有阿片受体激动剂活性。 通常，融合蛋白可以相对于不与血清蛋白融合的阿片样物质受体激动剂在体内或体外表现出延长的或稳定的阿片受体激动剂活性。

公开(公告)号：WO2008019368A2

公开(公告)日：2008-02-14

申请号：PCT/US2007/075361

申请日：2007-08-07

Applicant: COGENESYS, INC. ,  BELL, Adam, C. ,  ROSEN, Craig, A. ,  SANYAL, Indrajit ,  ZHAO, Qinghai

Inventor： BELL, Adam, C. ,  ROSEN, Craig, A. ,  SANYAL, Indrajit ,  ZHAO, Qinghai

IPC: C07K14/62 ,  C07K14/765 ,  A61K38/28 ,  A61K38/38 ,  A61P3/10 ,  C12N15/17 ,  C12N5/10

CPC classification number: C07K14/62 ,  A61K38/28 ,  C07K14/765 ,  C07K2319/35 ,  C12N15/62

Abstract: Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin activity in vivo or in vitro relative to insulin that is not fused to albumin. The fusion proteins may be formulated as aerosol compositions.

Abstract translation: 公开了包含与具有胰岛素活性的多肽融合的白蛋白的融合蛋白。 融合蛋白可以包括与胰岛素融合的白蛋白或胰岛素类似物。 特别地，融合蛋白可以包括与单链胰岛素类似物融合的白蛋白。 相对于未与白蛋白融合的胰岛素，融合蛋白可在体内或体外表现出延长的胰岛素活性。 融合蛋白可以配制成气溶胶组合物。

公开(公告)号：WO2008052043A9

公开(公告)日：2008-07-31

申请号：PCT/US2007082363

申请日：2007-10-24

Applicant: COGENESYS INC ,  ROSEN CRAIG A ,  BELL ADAM C ,  SANYAL INDRAJIT ,  LAFLEUR DAVID

Inventor： ROSEN CRAIG A ,  BELL ADAM C ,  SANYAL INDRAJIT ,  LAFLEUR DAVID

IPC: C07K14/435

CPC classification number: C07K14/665 ,  C07K14/4715 ,  C07K2319/00

Abstract: Disclosed are fusion proteins that include an opioid receptor agonist protein, or a fragment, variant, or an analog thereof fused to a serum protein. Suitable serum proteins for the fusion proteins in albumin, alpha- fetoprotein (AFP) and albumin- AFP hybrid proteins. The fusion proteins have opioid receptor agonist activity. Typically, the fusion proteins may exhibit extended or stabilized opioid receptor agonist activity in vivo or in vitro relative to an opioid receptor agonist that is not fused to the serum protein.

Abstract translation: 公开了融合蛋白，其包含与血清蛋白融合的阿片受体激动蛋白或其片段，变体或类似物。 白蛋白，甲胎蛋白（AFP）和白蛋白-AFP杂合蛋白中融合蛋白的合适血清蛋白。 融合蛋白具有阿片受体激动剂活性。 典型地，融合蛋白相对于未与血清蛋白融合的阿片受体激动剂，可在体内或体外表现出延长的或稳定的阿片受体激动剂活性。

公开(公告)号：WO2008052043A3

公开(公告)日：2009-01-08

申请号：PCT/US2007082363

申请日：2007-10-24

Applicant: COGENESYS INC ,  ROSEN CRAIG A ,  BELL ADAM C ,  SANYAL INDRAJIT ,  LAFLEUR DAVID

Inventor： ROSEN CRAIG A ,  BELL ADAM C ,  SANYAL INDRAJIT ,  LAFLEUR DAVID

IPC: C07K14/665 ,  A61K38/22 ,  C07K14/575 ,  C12N15/62

CPC classification number: C07K14/665 ,  C07K14/4715 ,  C07K2319/00

Abstract: Disclosed are fusion proteins that include an opioid receptor agonist protein, or a fragment, variant, or an analog thereof fused to a serum protein. Suitable serum proteins for the fusion proteins in albumin, alpha- fetoprotein (AFP) and albumin- AFP hybrid proteins. The fusion proteins have opioid receptor agonist activity. Typically, the fusion proteins may exhibit extended or stabilized opioid receptor agonist activity in vivo or in vitro relative to an opioid receptor agonist that is not fused to the serum protein.

Abstract translation: 公开了融合蛋白，其包含与血清蛋白融合的阿片受体激动剂蛋白或其片段，变体或类似物。 用于白蛋白，甲胎蛋白（AFP）和白蛋白AFP杂交蛋白中的融合蛋白的合适的血清蛋白。 融合蛋白具有阿片受体激动剂活性。 通常，融合蛋白可以相对于不与血清蛋白融合的阿片样物质受体激动剂在体内或体外表现出延长的或稳定的阿片受体激动剂活性。

公开(公告)号：WO2007126546A1

公开(公告)日：2007-11-08

申请号：PCT/US2007/005711

申请日：2007-03-07

Applicant: COGENESYS, INC. ,  ROSEN, Craig, A. ,  BELL, Adam, C. ,  SANYAL, Indrajit

Inventor： ROSEN, Craig, A. ,  BELL, Adam, C. ,  SANYAL, Indrajit

IPC: C07K14/47

CPC classification number: C07K14/4715 ,  A61K39/00 ,  A61K2039/6031 ,  C07K2319/31 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/464 ,  Y02A50/466 ,  Y02A50/472 ,  Y02A50/484

Abstract: The invention relates generally to fusion proteins comprising at least one therapeutic protein or vaccine antigen and alpha fetoprotein. The therapeutic protein or vaccine antigen can be, for example, a peptide, antibody, fragment thereof, or variant thereof. The therapeutic protein or vaccine antigen is fused to alpha-fetoprotein, an alpha-fetoprotein fragment, or an alpha-fetoprotein variant. Also encompassed by the invention are nucleic acids encoding the fusion proteins of the invention, vectors comprising such nucleic acids, and host cells transformed with such nucleic acids and/or vectors. Methods of making and using the fusion proteins, nucleic acids, vectors, and host cells are also encompassed by the invention.

Abstract translation: 本发明一般涉及包含至少一种治疗性蛋白质或疫苗抗原和甲胎蛋白的融合蛋白。 治疗性蛋白质或疫苗抗原可以是例如肽，抗体，其片段或其变体。 治疗性蛋白质或疫苗抗原与甲胎蛋白，甲胎蛋白片段或甲胎蛋白变体融合。 本发明还包括编码本发明的融合蛋白的核酸，包含该核酸的载体和用这种核酸和/或载体转化的宿主细胞。 制备和使用融合蛋白，核酸，载体和宿主细胞的方法也包括在本发明中。

公开(公告)号：WO2008019368A3

公开(公告)日：2008-12-24

申请号：PCT/US2007075361

申请日：2007-08-07

Applicant: COGENESYS INC ,  BELL ADAM C ,  ROSEN CRAIG A ,  SANYAL INDRAJIT ,  ZHAO QINGHAI

Inventor： BELL ADAM C ,  ROSEN CRAIG A ,  SANYAL INDRAJIT ,  ZHAO QINGHAI

IPC: C07K14/62 ,  A61K38/28 ,  A61K38/38 ,  A61P3/10 ,  C07K14/765 ,  C12N5/10 ,  C12N15/17

CPC classification number: C07K14/62 ,  A61K38/28 ,  C07K14/765 ,  C07K2319/35 ,  C12N15/62

Abstract: Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin activity in vivo or in vitro relative to insulin that is not fused to albumin. The fusion proteins may be formulated as aerosol compositions.

Abstract translation: 公开了融合蛋白，其包括与具有胰岛素活性的多肽融合的白蛋白。 融合蛋白可包括与胰岛素或胰岛素类似物融合的白蛋白。 特别地，融合蛋白可以包括与单链胰岛素类似物融合的白蛋白。 融合蛋白可以在体内或体外相对于不与白蛋白融合的胰岛素表现出延长的胰岛素活性。 融合蛋白可以配制成气溶胶组合物。

公开(公告)号：WO0102553A2

公开(公告)日：2001-01-11

申请号：PCT/US0010509

申请日：2000-04-19

Applicant: US HEALTH ,  BELL ADAM C ,  WEST ADAM G ,  FELSENFELD GARY

Inventor： BELL ADAM C ,  WEST ADAM G ,  FELSENFELD GARY

IPC: C12N15/09 ,  A61K48/00 ,  C12N5/10 ,  C12N15/63 ,  C12N15/00

CPC classification number: C12N15/63

Abstract: An insulator element shown to be both necessary and sufficient for the enhancer blocking activity in human cells is described. The insulator element of the invention is a 42 base pair DNA molecule having specific enhancer blocking activity for regulation of gene expression. The insulator element has also been shown to be the core binding site for CTCF, a DNA binding protein that is highly conserved in vertebrates. In addition, an insulator element containing CTCF binding sites has been identified in the region of the Igf 2 locus which is methylated exclusively on the paternal allele. Methylation of the insulator sequence abolishes the ability of CTCF to bind to the insulator and results in loss of enhancer-blocking activity.

Abstract translation: 描述了对人类细胞中增强子阻断活性来说必要且充分的绝缘子元件。 本发明的绝缘子元件是具有特异性增强子阻断活性以调节基因表达的42个碱基对的DNA分子。 绝缘子元件也被证明是CTCF的核心结合位点，CTCF是一种在脊椎动物中高度保守的DNA结合蛋白。 另外，在仅在父本等位基因上甲基化的Igf2基因座的区域中已经鉴定出含有CTCF结合位点的绝缘子元件。 绝缘子序列的甲基化消除了CTCF与绝缘子结合的能力并导致增强子阻断活性的丧失。